Subathra Ramamoorthy, Veranova, on when to escalate to structural elucidation and pair orthogonal techniques when characterizing an impurity.
News|Articles|July 8, 2021
LGM Pharma Launches Analytical Services for Drug Developers and Manufacturers
LGM Pharma will offer contract analytical testing and stability services to pharmaceutical developers and manufacturers.
Advertisement
LGM Pharma announced in a July 8, 2021 press release that it will now offer contract analytical testing and stability services to pharmaceutical developers and manufacturers, including compounding pharmacies. The company already conducts analytical services as part of its integrated contract development and manufacturing (CDMO) activities but is now offering its analytical services expertise and facilities as a standalone contract service.
“We are delighted to be able to offer our first-rate analytical and stability testing services to the broader community of drug manufacturers and developers,” said Shailesh Vengurlekar, senior vice-president, Quality & Regulatory Affairs at LGM Pharma, in the press release. “Our innovative approach to analytical and stability testing focuses on translating our deep understanding of data into actionable results.”
Vengurlekar noted that the company’s acquisition of Nexgen Pharma’s CDMO business in 2020 expanded its capabilities and facilities, allowing LGM Pharma to offer the contract testing service.
The company’s services include comprehensive analytical method development and validation processes that meet all current good manufacturing practice requirements and International Conference on Harmonisation (ICH) guidelines. LGM Pharma analyzes samples using accepted pharmacopoeia methods, and its on-site stability chambers are maintained per ICH guidelines. Testing provides the evidence needed to support shelf-life claims for FDA regulatory filings.
Source:
Advertisement
Related to this article
BMS-Tempus, Roche-Zymeworks, and LGM-Sannova deals show what AI data, trispecifics, and nitrosamine testing mean for CMC, QA, and development teams.
Nitin Kumar Swarnakar, PhD, global application lab manager at BASF, talks about spray drying for drying amorphous solid dispersions and Raman spectroscopy’s role as a quantitative analytical tool.
Nitin Kumar Swarnakar, PhD, global application lab manager at BASF in Tarrytown, spoke with PharmTech at AAPS PharmSci 360 about formulation and characterization challenges for amorphous solid dispersions.
FDA draft guidance on individualized genome editing lets BLAs add patient-specific variants without new trials, shifting evidence to CMC assay data.
Vibha Jawa, PhD, chief scientific officer at EpiVax, explains why the need for animal studies varies by modality and what it takes for organ-on-chip and other human-relevant models to replace these studies in IND-enabling toxicology work.
Jane Zhang of ETCH Sourcing explains why geopolitics, transparency, and partnership now weigh as heavily as cost and quality when companies choose suppliers, in this episode of Ask the Expert, moderated by Susan J. Schniepp of Nelson Labs.
The PharmTech team focused on its coverage of AAPS PharmSci 360 this week, conducting interviews with experts on a range of topics including formulation platforms, AI, amorphous solid dispersions, and animal studies.
Advertisement
Advertisement
Trending on Pharmaceutical Technology
1
From URS to Acceptance Evidence: Defining and Testing Interfaces in Pen Injector Assembly
2
AAPS PharmSci 360 2026: IND-Enabling Studies vs Animal Data
3
PharmTech Weekly Roundup—October 23, 2026: CMC Considerations, Rare Disease Development, Standards Harmonization
4
Why AI Model Updates Need Change Control: AAPS PharmSci 360 2026
5